|Day Low/High||59.25 / 60.39|
|52 Wk Low/High||46.47 / 64.82|
U.S. regulators say they will not approve Novo Nordisk's new long-acting insulin Tresiba until more testing of it is conducted.
This sector is outperforming, and these two names are compelling on a pullback.
This metric is a prime indicator of financial health, and these health-related stock stand out.
Here is this week's roundup of the dumbest actions on Wall Street.
In the large, but targeted, market for diabetes drugs, two very different companies share a deeper commitment.
The sector is in the doldrums, yet the prospects for these three names are quite strong.